EFFICACY OF SONROTOCLAX VERSUS PIRTOBRUTINIB IN POST–BRUTON TYROSINE KINASE INHIBITOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: AN INDIRECT COMPARISON

EHA Library, Toby A. Eyre, 4210176

GLOBAL TRENDS IN CLINICIAN PREPAREDNESS FOR FRONTLINE BTK INHIBITOR–BASED THERAPY IN MANTLE CELL LYMPHOMA: A LONGITUDINAL EDUCATIONAL OUTCOMES ANALYSIS

EHA Library, Carmine DeLuca, 4210177

MUTATION STATUS OF THE CREBBP GENE IN AGGRESSIVE FOLLICULAR LYMPHOMA 3A-3B (14;18)-NEGATIVE.

EHA Library, Anna Smolianinova, 4210178

EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE OF THE LUNG: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Yu Qiu, 4210181

EFFICACY, SAFETY, AND NGS ANALYSIS OF ORELABRUTINIB COMBINED WITH OBINUTUZUMAB IN UNTREATED MARGINAL ZONE LYMPHOMA

EHA Library, Honglan Qian, 4210183

OPTIMIZING DIAGNOSTIC STRATEGY IN ADULT LYMPHADENOPATHY: EXCISIONAL VERSUS CORE NEEDLE BIOPSY IN A DEDICATED LYMPHADENOPATHY CLINIC

EHA Library, Marta Diaz-Lopez, 4210184

CUTANEOUS T-CELL LYMPHOMA EPIDEMIOLOGY IN THE UNITED STATES: A REAL-WORLD DATA ANALYSIS OF ADMINISTRATIVE CLAIMS

EHA Library, Pierluigi Porcu, 4210186

TNFRSF14 MUTATIONS ARE ASSOCIATED WITH INCREASED RISK OF HISTOLOGICAL TRANSFORMATION AND POOR PROGNOSIS IN FOLLICULAR LYMPHOMA

EHA Library, Xia Zhao, 4210190

CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH LYMPHOPLASMACYTIC LYMPHOMA: A REAL-WORLD MULTI-CENTER STUDY FROM CHINA

EHA Library, Xiao Gao, 4210191

SURVIVAL AND RISK STRATIFICATION IN LEUKEMIC-PHASE FOLLICULAR LYMPHOMA: OUTCOMES COMPARABLE TO CONVENTIONAL DISEASE

EHA Library, Zheng Fan, 4210192

T-CELL CLONALITY OF UNCERTAIN SIGNIFICANCE: CLINICAL AND LABORATORY CORRELATION

EHA Library, Phyo Thazin Myint, 4210193

REAL-WORLD MULTIDIMENSIONAL COMPARISON OF FIRST-LINE IMMUNOCHEMOTHERAPY VERSUS ORELABRUTINIB-BASED THERAPY IN PULMONARY MALT LYMPHOMA: EFFICACY, SAFETY, AND PROGNOSTIC PERIPHERAL BIOMARKERS

EHA Library, Zhenqian Huang, 4210194

FIRST-LINE KCD-R FOR WALDENSTRÖM MACROGLOBULINAEMIA IS ASSOCIATED WITH MORE SEVERE HYPOGAMMAGLOBULINAEMIA BUT NOT INFECTIONS REQUIRING IVIG OR HOSPITALISATION COMPARED TO BR OR ZANUBRUTINIB

EHA Library, James Di Palma-Grisi, 4210195

CLINICAL, PATHOLOGICAL, AND MOLECULAR LANDSCAPE AND PROGNOSTIC FACTORS OF DIFFUSE LARGE B-CELL LYMPHOMA TRANSFORMED FROM FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Xiaoli Yuan, 4210201

PROGNOSTIC DETERMINANTS IN EXTRANODAL MARGINAL ZONE LYMPHOMA

EHA Library, Maha Charfi, 4210203

GOLSEEK-4: A PHASE 3, RANDOMIZED STUDY OF GOLCADOMIDE, A POTENTIAL, FIRST-IN-CLASS, ORAL CELMOD, + RITUXIMAB VS INVESTIGATOR’S CHOICE IN PATIENTS WITH R/R FL WHO RECEIVED ≥1 LINE OF SYSTEMIC THERAPY

EHA Library, Muhit Ozcan, 4210205

ORELABRUTINIB PLUS ANTI-CD20 MONOCLONAL ANTIBODY WITH OR WITHOUT IMMUNOMODULATORY AGENT FOLLOWED BY ORELABRUTINIB MAINTENANCE THERAPY IN MARGINAL ZONE LYMPHOMA: A RETROSPECTIVE STUDY

EHA Library, Ting Niu, 4210206

EPIDEMIOLOGY AND OUTCOME OF MARGINAL ZONE LYMPHOMAS PATIENTS: A MULTICENTRIC STUDY FOR THE TUNISIAN INDOLENT LYMPHOMA STUDY GROUP

EHA Library, hela ghedira, 4210207

ESTABLISHING REAL-WORLD SURVIVAL BENCHMARKS FOR MANTLE CELL LYMPHOMA PRIOR TO FRONTLINE BTK INHIBITORS: A MULTICENTRE STUDY

EHA Library, Lawrence Cheng Kiat Ng, 4210208

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN ADVANCED-STAGE MYCOSIS FUNGOIDES: A 26-CASE RETROSPECTIVE COHORT STUDY FROM CHINA

EHA Library, Ming Jiang, 4210210

HEPATITIS B CORE ANTIBODY POSITIVITY AS AN INDEPENDENT ADVERSE PROGNOSTIC FACTOR IN ELDERLY PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Chunyuan Li, 4210217

PRELIMINARY RESULTS OF A RETROSPECTIVE STUDY OF ORELABRUTINIB FOLLOWING WITH CHEMOTHERAPY FOR TREATMENT-NAIVE MARGINAL ZONE LYMPHOMA

EHA Library, Kun Yang, 4210218

BEYOND STANDARD GELF: REDEFINING PROGNOSTIC RISK STRATIFICATION IN FOLLICULAR LYMPHOMA

EHA Library, Efe Semercioğlu, 4210219

REAL-WORLD OUTCOMES OF R-CHOP PLUS RITUXIMAB MAINTENANCE AS FIRST-LINE THERAPY IN FOLLICULAR LYMPHOMA: A NATION-WIDE MULTICENTER 10-YEAR  TUNISIAN STUDY

EHA Library, Nesrine Ben Sayed, 4210220

THERAPEUTIC OUTCOMES OF YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA: A TUNISIAN MULTICENTER REAL-WORLD STUDY

EHA Library, Zaineb Mlayah, 4210223

EFFECTIVENESS AND SAFETY OF ORELABRUTINIB-BASED REGIMENS IN MARGINAL ZONE LYMPHOMA: A REAL-WORLD RETROSPECTIVE STUDY

EHA Library, TongJuan Li, 4210227

OUTCOMES OF FIRST-LINE BTK INHIBITOR- BASED THERAPY IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA

EHA Library, Julia Zhuravleva, 4210229

PRIMARY PULMONARY MARGINAL ZONE LYMPHOMA: A MULTICENTER EXPERIENCE WITH 14 PATIENTS TREATED WITH ORELABRUTINIB-BASED THERAPY

EHA Library, Hongbing Ma, 4210230

HIGH TREATMENT ATTRITION IN MANTLE CELL LYMPHOMA DESPITE PRESERVED RESPONSE: A REAL-WORLD SINGLE TERTIARY CANCER CENTER EXPERIENCE FROM INDONESIA

EHA Library, Shafira Puspadina, 4210231

BONE MARROW INVOLVEMENT PATTERNS IN MANTLE CELL LYMPHOMA: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Yutong Wang, 4210232

PROGNOSTIC IMPACT OF FLIPI, FLIPI2, GELF SCORE, AND POD24 IN FOLLICULAR LYMPHOMA: A REAL-WORLD 10-YEAR MULTICENTER TUNISIAN STUDY

EHA Library, Nesrine Ben Sayed, 4210233

CLINICAL PRESENTATION AND OUTCOMES OF SPLENIC MARGINAL ZONE LYMPHOMA: A MULTICENTER TUNISIAN STUDY

EHA Library, sayadi malek, 4210234

NODAL MARGINAL ZONE LYMPHOMA: RESULTS FROM A TUNISIAN MULTICENTER STUDY

EHA Library, Slama Nader, 4210238

EARLY PROGRESSION WITHIN 24 MONTHS PREDICTS SURVIVAL ACROSS NODAL NON-HODGKIN LYMPHOMA INDEPENDENT OF HISTOLOGY AND PRIMARY LOCALIZATION

EHA Library, Victor Tomacinschii, 4210240

DEVELOPMENT OF SPLENIC B-CELL LYMPHOMA/LEUKEMIA WITH PROMINENT NUCLEOLI IN A PATIENT WITH PRIMARY MYELOFIBROSIS

EHA Library, Abdulkadir Karismaz, 4210243

PROGNOSTIC FACTORS AND THERAPEUTIC OUTCOMES OF MANTLE CELL LYMPHOMA IN ELDERLY PATIENTS: A TUNISIAN MULTICENTER RETROSPECTIVE STUDY

EHA Library, wided cherif, 4210244

FOLLICULAR LYMPHOMA IN TUNISIA: A DECADE-LONG MULTICENTER RETROSPECTIVE REAL-WORLD STUDY OF CLINICAL FEATURES AND OUTCOMES

EHA Library, Nesrine Ben Sayed, 4210245

CLINICOBIOLOGICAL FEATURES AND PROGNOSTIC IMPACT OF FIRST-LINE THERAPY IN MARGINAL ZONE LYMPHOMAS: A 44-PATIENT SINGLE-CENTER STUDY

EHA Library, Souad Fennan, 4210246

HISTOLOGICAL TRANSFORMATION OF MARGINAL ZONE LYMPHOMA INTO HIGH-GRADE LYMPHOMA

EHA Library, Maha Charfi, 4210248

ASSOCIATION OF THE NUMBER OF P16INK4A-POSITIVE TUMOR CELLS WITH THE PRESENCE OF PATHOGENIC MISSENSE VARIANTS OF THE TP53 GENE IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Maria Berdnikova, 4210250

THE USE OF RITUXIMAB IN THE TREATMENT OF NON-HODGKIN LYMPHOMAS IN PREGNANT WOMEN: MATERNAL AND INFANT OUTCOMES

EHA Library, Inna Krasilnikova, 4210251

CHANGES IN THE UTILIZATION OF INNOVATIVE THERAPIES INCLUDING BISPECIFIC ANTIBODIES AND SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AROUND 2024

EHA Library, Haiwen Huang, 4210253

DEVELOPMENT AND VALIDATION OF CTRS-AC FOR PREDICTING SEVERE CHEMOTHERAPY TOXICITY IN ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Xiangxiang Zhou, 4210256

REAL-WORLD OUTCOMES OF POLATUZUMAB VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE (POLA-R-CHP) IN HIV-ASSOCIATED LARGE B-CELL LYMPHOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS

EHA Library, James Paterson, 4210260

EFFICACY AND SAFETY OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN SECONDARY CNS LYMPHOMAS REFRACTORY TO HIGH-DOSE METHOTREXATE (HD-MTX)-BASED CHEMOIMMUNOTHERAPY

EHA Library, Piera Angelillo, 4210261

GLOBAL VARIATION IN CAR T CELL THERAPY PRACTICE PATTERNS FOR LBCL: QUANTITATIVE RESEARCH FINDINGS

EHA Library, Samuel Yamshon, 4210262

BEYOND THE IPI: INFLAMMATION–NUTRITION-BASED INDICES IN THE RISK ASSESSMENT OF DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Zorica Cvetković, 4210263

REAL-WORLD OUTCOMES OF RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) IN R/R LARGE B-CELL LYMPHOMA

EHA Library, Zixun Yan, 4210264

TREATMENT LANDSCAPE AND OUTCOME IN PATIENTS WITH STAGE I-II PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Diana Al-Sarayfi, 4210265

PET-INTEGRATED NOMOGRAMS FOR SURVIVAL PREDICTION IN PATIENTS WITH LARGE B-CELL LYMPHOMA TREATED WITH CAR T-CELL THERAPY

EHA Library, Beatrice Casadei, 4210266

EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN’S LYMPHOMA: REAL-WORLD DATA IN CHINESE POPULATION

EHA Library, Li Wang, 4210268

AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN BRAZIL: THE IMPACT OF CAR T-CELL THERAPY WAIT TIME AND TREATMENT SEQUENCING

EHA Library, João De Holanda Farias, 4210270

INDEPENDENT VALIDATION OF THE INTERNATIONAL METABOLIC PROGNOSTIC INDEX (IMPI) ON EFFICACY AND SAFETY OF CAR-T IN PATIENTS WITH AGGRESSIVE LARGE B-CELL LYMPHOMA

EHA Library, Eugenio Galli, 4210271

OBSERVATIONS OF CAR T AND CARNEG BYSTANDER T CELL DYNAMICS FOLLOWING EPCORITAMAB TREATMENT IN R/R DLBCL

EHA Library, Kensuke Yanashima, 4210274

REAL-WORLD EXPERIENCE WITH POLATUZUMAB-R-BASED REGIMENS IN PREVIOUSLY UNTREATED LARGE B-CELL LYMPHOMA: A STUDY BY THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

EHA Library, Dino Dujmović, 4210275

INCIDENCE AND IMPACT OF MISDIAGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): AN ANALYSIS FROM LYMPHOMA COALITION'S 2024 GLOBAL PATIENT SURVEY ON LYMPHOMAS & CLL

EHA Library, Lorna Warwick, 4210277

A MACHINE LEARNING-ASSISTED PROGNOSTIC MODEL FOR PREDICTING OUTCOMES IN B-CELL LYMPHOMA PATIENTS WITH CONCOMITANT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: CONSTRUCTION AND INTERNAL VALIDATION

EHA Library, Luocheng Zhang, 4210278

COMPARATIVE SAFETY AND EFFICACY OF CAR T-CELL THERAPY AND BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: A META-ANALYSIS OF CLINICAL TRIALS AND REAL-WORLD STUDIES

EHA Library, Julia Wang, 4210175

BRUMIZE: REAL-WORLD ZANUBRUTINIB USE AND PRELIMINARY SAFETY IN R/R MARGINAL ZONE LYMPHOMA IN EUROPE

EHA Library, Côme Bommier, 4210182

ORELABRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: A REAL-WORLD RETROSPECTIVE STUDY

EHA Library, Wenjuan Yu, 4210185

IBRUTINIB MONOTHERAPY FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA : A POLISH LYMPHOMA RESEARCH GROUP (PLRG) REAL-WORLD STUDY

EHA Library, Joanna Romejko-Jarosińska, 4210187

SCALABLE SEMI-SUPERVISED INTERVAL EXERCISE IMPROVES AEROBIC FITNESS IN INDOLENT NON-HODGKIN LYMPHOMA

EHA Library, Courtney Wheatley-Guy, 4210188

A PROSPECTIVE, MULTICENTER, PHASE II STUDY OF ORELABRUTINIB COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

EHA Library, Lixia Sheng, 4210189

LOW DOSE RADIOTHERAPY COMBINED WITH OBUTINIB IMPROVES THE COMPLETE RESPONSE RATE OF TREATMENT FOR LOCALIZED OCULAR ADNEXAL EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA

EHA Library, Shaoxin Yang, 4210196

REAL-WORLD OUTCOMES OF ORELABRUTINIB-CONTAINING REGIMENS IN PREVIOUSLY UNTREATED PATIENTS WITH MARGINAL ZONE LYMPHOMA

EHA Library, Xun Lai, 4210197

IDENTIFYING GAPS IN TREATMENT OF FOLLICULAR LYMPHOMA WITH BISPECIFICS THROUGH ONLINE CONTINUING MEDICAL EDUCATION

EHA Library, Sarah Elizabeth Bomba, 4210198

DECIPHERING THE METABOLIC LINK TO MARGINAL ZONE LYMPHOMA THROUGH MENDELIAN RANDOMIZATION ANALYSIS

EHA Library, Yupiao Feng, 4210199

RESPONSE-ADAPTED ORELABRUTINIB AND RITUXIMAB WITH OR WITHOUT LENALIDOMIDE FOR UNTREATED MARGINAL ZONE LYMPHOMA

EHA Library, Lei Fan, 4210200

BASELINE CHARACTERISTICS AND CLINICAL FEATURES OF INDOLENT LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT: A MULTICENTER RETROSPECTIVE STUDY OF 39 CASES

EHA Library, Xixi Xiang, 4210202

ORELABRUTINIB WITH ANTI-CD20 MONOCLONAL ANTIBODIES IS HIGHLY EFFECTIVE AND WELL  TOLERATED AS FIRST-LINE THERAPY FOR MARGINAL ZONE LYMPHOMA

EHA Library, Na Yao, 4210211

ACALABRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF UNTREATED, ELDERLY OR YOUNG WITH LOW- TO INTERMEDIATE- RISK MANTLE CELL LYMPHOMA: AN EXPLORATORY, MULTI-CENTER, SINGLE-ARM, PHASE II STUDY

EHA Library, Qingqing Cai, 4210212

INCREASED EXPRESSION OF TIGIT(+)CD226(+)CD16(+)CD56(+) CELLS IN PATIENTS WITH AGVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Yang Liu, 4210213

RESULTS OF TREATMENT OF RELAPSE AND REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) IN REAL CLINICAL PRACTICE IN THE RUSSIAN FEDERATION.

EHA Library, Anna Smolianinova, 4210214

PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH (RDW) AT DIAGNOSIS IN FOLLICULAR LYMPHOMA.

EHA Library, Marta Diaz-Lopez, 4210215

CLINICAL AND EVOLUTIONARY CHARACTERISTICS OF MARGINAL ZONE LYMPHOMA: A SINGLE-CENTER ALGERIAN EXPERIENCE

EHA Library, Nassima Boulaziz, 4210216

CHEMO-FREE FIRST-LINE THERAPY IN FRAIL PATIENTS WITH MARGINAL AND MANTLE CELL NON-HODGKIN LYMPHOMA: OUR EXPERIENCE

EHA Library, Luca Pezzullo, 4210221

EFFICACY AND SAFETY OF ORELABRUTINIB COMBINED WITH LOW-DOSE RADIOTHERAPY IN TREATMENT-NAIVE MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA

EHA Library, Yamin Tan, 4210222

PROSPECTIVE EXPLORATION OF ZUBERITAMAB, LENALIDOMIDE COMBINED WITH ORELABRUTINIB (HRO) IN THE TREATMENT OF NEWLY DIAGNOSED MARGINAL ZONE LYMPHOMA.

EHA Library, Yu Qiu, 4210224

EXTRANODAL MARGINAL ZONE LYMPHOMA: CLINICAL FEATURES, PROGNOSTIC FACTORS AND TREATMENT OUTCOMES IN A TUNISIAN COHORT

EHA Library, Maha Charfi, 4210225

REAL-WORLD RETROSPECTIVE STUDY OF ORELABRUTINIB-BASED REGIMENS IN CHINESE PATIENTS WITH MARGINAL ZONE LYMPHOMA

EHA Library, Ziqian Wang, 4210226

A PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF ORELABRUTINIB COMBINED WITH R-CHEMO REGIMEN FOLLOWED BY ORELABRUTINIB MAINTENANCE THERAPY IN MZL

EHA Library, Haiyan Zhu, 4210228

ORELABRUTINIB PLUS VENETOCLAX IN PATIENTS WITH SPLENIC MARGINAL ZONE LYMPHOMA INTOLERANT TO RITUXIMAB

EHA Library, Zhilin Gao, 4210235

EFFICACY OF ULTRA-LOW-DOSE (ULD) RADIOTHERAPY IN MALT LYMPHOMA: REAL-WORLD DATA FROM AN UNIQUE BRAZILIAN CANCER CENTER

EHA Library, Talita Maira Bueno Da Silveira, 4210236

ANALYSIS OF RISK FACTORS FOR INFUSION-RELATED REACTIONS IN PATIENTS WITH B-CELL LYMPHOMA DURING OBINUTUZUMAB TREATMENT

EHA Library, Zi Wang, 4210237

REAL WORLD DATA ON TREATMENT OF RELAPSED/REFRACTORY INDOLENT LYMPHOMA WITH BISPECIFIC ANTIBODY MOSUNETUZUMAB – KROHEM EXPERIENCE

EHA Library, Barbara Dreta, 4210239

PROGNOSTIC DETERMINANTS IN SPLENIC MARGINAL ZONE LYMPHOMA

EHA Library, sayadi malek, 4210241

PROGNOSTIC DETERMINANTS IN NODAL MARGINAL ZONE LYMPHOMA

EHA Library, sayadi malek, 4210242

TYPE I CRYOGLOBULINEMIA ASSOCIATED WITH MARGINAL ZONE LYMPHOMA COMPLICATED BY THROMBOTIC MICROANGIOPATHY AND CRITICAL DISTAL ISCHEMIA AFTER RITUXIMAB

EHA Library, Nataly Ibarra, 4210247

PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH (RDW) AT DIAGNOSIS IN MANTLE CELL LYMPHOMA.

EHA Library, Sunil Lakhwani, 4210249

LACK OF SURVIVAL BENEFIT WITH TEMOZOLOMIDE MAINTENANCE AFTER HIGH-DOSE METHOTREXATE TREATMENT IN PRIMARY CNS LYMPHOMA - A REAL-WORLD ANALYSIS FROM TWO SWEDISH CENTRES

EHA Library, Jenni Niemi, 4210254

AN ANATOMY-INFORMED CLASSIFICATION STRATIFIES PRIMARY TESTICULAR LYMPHOMA AND DISTINGUISHES IT FROM SYSTEMIC DLBCL WITH TESTICULAR INVOLVEMENT AT DIAGNOSIS: A RETROSPECTIVE COHORT STUDY

EHA Library, Ying Shan, 4210255

THE IMPACT OF DIETETICS AND PHYSIOTHERAPY PREHABILITATION ON THE CAR-T PATIENT

EHA Library, Joanna Sinnos, 4210257

EFFICACY AND TOXICITY OF CYTARABINE IN FIRST-LINE INDUCTION THERAPY FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Lu Cui, 4210258

REAL WORLD DATA WITH POLATUZUMAB VEDOTIN TREATMENT IN THE FRONT LINE OF DLBCL – NATIONAL EXPERIENCE

EHA Library, Lucka Boltezar, 4210259

SURVIVAL OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA DEPENDING ON THE NUMBER OF EZH2- AND PSTAT3-POSITIVE TUMOR CELLS

EHA Library, Elena Vaneeva, 4210267

RIBOSOME BIOGENESIS–DRIVEN THERAPEUTIC RESISTANCE IN DLBCL: BIOLOGICAL MECHANISMS AND TARGETED INTERVENTION STRATEGIES

EHA Library, MinXing Yue, 4210269

EARLY LONGITUDINAL HEALTH-RELATED QUALITY OF LIFE (HRQOL) CHANGES WITH TAFASITAMAB–LENALIDOMIDE IN TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): INTERIM PRO-MIND

EHA Library, Alice Di Rocco, 4210272

PRE-TREATMENT ANTIBIOTIC EXPOSURE AND OUTCOMES AFTER BISPECIFIC ANTIBODY THERAPY IN B-CELL NON-HODGKIN LYMPHOMA: A SINGLE-CENTRE RETROSPECTIVE STUDY

EHA Library, Ana Cuervo Fonseca, 4210273

DIFFUSION MRI–DERIVED QUANTITATIVE METRICS IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Martine Nørskov, 4210276

EFFICACY AND SAFETY OF THE POLATUZUMAB, ACALABRUTINIB, RITUXIMAB, AND LENALIDOMIDE (POLA-AR2) REGIMEN AS FIRST-LINE THERAPY IN UNFIT OR FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Haiwen Huang, 4210279